" "    This is perilous for a company that has seen its market cap fall Valeant from over $ 40 billion to around $ 4 . 6 billion over the last year .    Accusations of fraud    drug price gouging have sent investors    fleeing from the company , and    holding over $    billion in    debt .The company    annual report    ( and any    reduction in cash flow hampering its ability to pay it ) as       risk .    